CAJ | 학술논문

目的建立ADVIA 120/2120血细胞分析仪复检规则和不同系列血细胞分析仪的通用复检规则.方法应用ADVIA120/2120血细胞分析仪检测2400份标本(含恶性血液病标本6份),其中1200份标本同时应用Sysmex XE-2100和Beckman-Coulter LH750血细胞分析仪检测,并均进行血涂片显微镜检查(镜检),对检测结果进行统计分析,参考国际血细胞分析仪复检规则并进行适当调整建立新的复检规则.随机选择300份标本验证新建立的复检规则.结果根据国际血细胞分析仪复检规则和我国血液学专家制定的涂片镜检阳性标准进行统计分析,ADVIA 120/2120血细胞分析仪检测的2400份标本真阳性率22.1%(530份),假阳性率28.1%(675份),真阴性率44.3%(1063份),假阴性率5.5%(132份),复检率50.2%(1205份),假阴性率超出最大可接受限(5.0%).修改涂片镜检阳性标准(提高中性杆状核粒细胞、嗜酸粒细胞、嗜碱粒细胞和单核细胞百分比)并对国际血细胞分析仪复检规则进行适当调整后建立新的复检规则,重新进行统计分析,真阳性率为15.5%(371份),假阳性率18.7%(449份),真阴性率61.6%(1479份),假阴性率4.2%(101份),复检率34.2%(821份),恶性血液病标本无漏检.在ADVIA 120/2120血细胞分析仪复检规则的基础上添加Sysmex XE-2100和Beckman-Coulter LH750血细胞分析仪特异参数后提出了通用复检规则,统计分析3种血细胞分析仪同时测定的1200份标本,假阴性率分别为4.3%、4.6%和4.6%,假阳性率分别为14.7%、17.5%和12.7%,均未漏检恶性血液病标本.验证试验中3种仪器的假阴性率分别为3.8%、4.3%和4.0%.结论建立了适用于大型综合性医院ADVIA 120/2120血细胞分析仪临床应用的复检规则和适用于3种不同系列血细胞分析仪的通用复检规则.
목적 건립ADVIA 120/2120혈세포분석의복검규칙화불동계렬혈세포분석의적통용복검규칙.방법 응용ADVIA120/2120혈세포분석의검측2400빈표본(함악성혈액병표본6빈),기중1200빈표본동시응용Sysmex XE-2100화Beckman-Coulter LH750혈세포분석의검측,병균진행혈도편현미경검사(경검),대검측결과진행통계분석,삼고국제혈세포분석의복검규칙병진행괄당조정건립신적복검규칙.수궤선택300빈표본험증신건립적복검규칙.결과 근거국제혈세포분석의복검규칙화아국혈액학전가제정적도편경검양성표준진행통계분석,ADVIA 120/2120혈세포분석의검측적2400빈표본진양성솔22.1%(530빈),가양성솔28.1%(675빈),진음성솔44.3%(1063빈),가음성솔5.5%(132빈),복검솔50.2%(1205빈),가음성솔초출최대가접수한(5.0%).수개도편경검양성표준(제고중성간상핵립세포、기산립세포、기감립세포화단핵세포백분비)병대국제혈세포분석의복검규칙진행괄당조정후건립신적복검규칙,중신진행통계분석,진양성솔위15.5%(371빈),가양성솔18.7%(449빈),진음성솔61.6%(1479빈),가음성솔4.2%(101빈),복검솔34.2%(821빈),악성혈액병표본무루검.재ADVIA 120/2120혈세포분석의복검규칙적기출상첨가Sysmex XE-2100화Beckman-Coulter LH750혈세포분석의특이삼수후제출료통용복검규칙,통계분석3충혈세포분석의동시측정적1200빈표본,가음성솔분별위4.3%、4.6%화4.6%,가양성솔분별위14.7%、17.5%화12.7%,균미루검악성혈액병표본.험증시험중3충의기적가음성솔분별위3.8%、4.3%화4.0%.결론 건립료괄용우대형종합성의원ADVIA 120/2120혈세포분석의림상응용적복검규칙화괄용우3충불동계렬혈세포분석의적통용복검규칙.
objective To establish the suitable review criteria for ADVIA 120/2120 and those for different series of hematology analyzers.Methods A total of 2400 samples,including 6 blood neoplasms,were detected with ADVIA 120/2120 hematology analyzer,in which 1200 samples were detected by Sysmex XE-2100 and Beckman-Coulter LH750 hematology analyzers.In the meantime,blood smears were reviewed,and the results were analyzed statistically.The new review criteria were established by consulting and modifying the one as recommended by an international consensus group.Finally 300 samples were selected to validate the new review criteria.Results The results of 2400 samples detected by ADVIA 120/2120 hematology analyzer were analyzed statistically according to the international consensus review rules and blood smear positive criteria formulated by Chinese experts.The true positive rate was 22.1%(n=530),false positive rate 28.1%(n=675),true negative rate 44.3%(n=1063),false negative rate 5.5%(n=132),and the smear review rate 50.2%(n=1205).The false negative rate was over the acceptable limit of 5%.The new review criteria were established by amending the blcod smear positive criteria,i.e.increasing the percentage of band neutrophils,eosinophils,basophils and monocytes and adjusting the international consensus review rules.Then the results were re-analyzed.The true positive rate.false positive rate,true negative rate and false negative rate were 15.5%(n=371),18.7%(n=449),61.6%(n=1479) and 4.2%(n=101) respectively.The smear review rate was 34.2%(n=821) and no specimen of blood neoplasms was missed.On that basis,the current review criteria for ADVIA 120/2120,XE-2100 and LH750 hematology analyzer were proposed by adding some specific parameters.The results of 1200 samples with three instruments were analyzed according to the current criteria.And the false negative rates were 4.3%,4.6% and 4.6%,and false positive rate 14.7%,17.5%and 12.7% respectively.And no specimen of blood neoplasm Was missed.The false negative rates of three instruments were 3.8%,4.3% and 4.0% in validation teses.Conclusion The review criteria for three difierent series of hematology analyzers have been formulated for large general hospitals.